Convergent Therapeutics
Next-Gen Targeted Radiotherapies
United States · $130.0M raised
- Employees
- 11–50
- Business Model
- B2B
- Website
- convergentrx.com
- Total Funding
- $130.0M
- Last Round
- $40.0M Extension RoundAug 2024
- Rounds
- 2
About
Convergent Therapeutics is a clinical-stage biotechnology company developing next-generation targeted radiopharmaceutical therapies for prostate cancer and solid tumors.
Summary
Convergent Therapeutics is a Biotech company based in United States. It has raised $130.0M in total across 2 rounds, most recently a $40.0M Extension Round round in Aug 2024. Investors include Novo Holdings A/S, OrbiMed and RA Capital Management.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...